Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2016-04-28 Interim / Quarterly Rep…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Q1 16 NL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Eerste Kwartaalverslag 2016' (First Quarter Report 2016) for the Galapagos Group. It contains detailed financial statements, management discussion and analysis (MDA), operational highlights, and key performance indicators for the three-month period ending March 31, 2016. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2016
2016-04-28 Dutch
Q1 16_final.pdf
Earnings Release Classification · 99% confidence The document is titled with a headline announcing 'Galapagos kick-starts 2016 with Q1 cash position of €988 M' and explicitly states it 'announces its unaudited first quarter results'. It contains key financial figures for Q1 2016 (Revenues, Net profit, Cash position) presented in a summary format, along with R&D progress highlights. This structure is characteristic of an Earnings Release (ER), which provides initial highlights of periodical financial results. Although it mentions a more detailed 'Q1 2016 report' is published online, the document itself serves as the primary, immediate announcement of the results, fitting the definition of an Earnings Release (ER) better than a comprehensive Interim Report (IR) or a mere Report Publication Announcement (RPA), given the inclusion of detailed key figures and management commentary. The length (9296 chars) is substantial enough to contain more than just a notification of publication. It is a summary of the period's performance. Q1 2016
2016-04-28 English
Q1 16 _final_NL.pdf
Earnings Release Classification · 98% confidence The document is titled with a date and a headline announcing financial results for the first three months (Q1 2016), including specific figures for revenue (€14.8 million) and net profit (€35.9 million). It explicitly states it is announcing 'niet-geauditeerde resultaten over het eerst kwartaal' (unaudited results for the first quarter) and includes a detailed table of key financial figures for Q1 2016 compared to Q1 2015. This content strongly aligns with an Earnings Release (ER), which provides initial highlights and key figures for a reporting period shorter than a year. Although it mentions a more comprehensive report is available online, the document itself contains the core results announcement, making ER the most appropriate classification over RPA or IR (which is for comprehensive interim reports). Q1 2016
2016-04-28 Dutch
Galapagos reports additional data with filgotinib from the Phase 2 FITZROY study
Earnings Release Classification · 95% confidence The document is a press release dated April 21, 2016, announcing 'aanvullende data' (additional data) from the Phase 2 FITZROY study for the drug filgotinib in Crohn's disease. It highlights key results (clinical response maintained, safety profile) and mentions future plans (Phase 3 start in 2016, submission to medical conferences). This format—a concise announcement of recent clinical trial results, often including forward-looking statements and contact information, but not the full, comprehensive financial report (like a 10-K or IR)—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical progress. Since it focuses purely on clinical trial results and pipeline updates rather than quarterly financial performance highlights, it aligns best with the general category for significant operational news releases. Given the options, 'ER' (Earnings Release) is often used broadly for period-end results announcements, but this is specifically a clinical data release. However, in the context of standard regulatory filings, announcements of clinical trial data updates are often categorized as general operational news. Since there is no specific 'Clinical Trial Update' code, and this is a formal announcement of results, it is closest to an 'ER' if interpreted as a periodic results announcement, or 'RNS' if treated as a general regulatory announcement. Given the structure (headline results, detailed background, contact info), it functions as a primary announcement of new information. Since it is not a full financial report (10-K, IR) or a proxy for a financial report (ER usually contains key financial metrics), and it is a formal announcement of clinical progress, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate fallback for significant, non-standard financial disclosures, although 'ER' is plausible if the database uses it for all period-end updates. I will select 'RNS' as it is a specific clinical data update announcement, not a standard earnings report. Q2 2016
2016-04-22 English
Galapagos reports additional data with filgotinib from the Phase 2 FITZROY study
Regulatory Filings Classification · 95% confidence The document is dated April 21, 2016, and is titled "Galapagos reports additional data with filgotinib from the Phase 2 FITZROY study." It details clinical trial results (Phase 2 data up to 20 weeks) for a drug candidate (filgotinib) in Crohn's disease. This content is characteristic of an announcement summarizing recent scientific or clinical findings, often released before a full quarterly or annual report. It is not a full Annual Report (10-K), an Audit Report (AR), or a formal Earnings Release (ER) which typically focuses on revenue/profit figures. Since it is a specific announcement of clinical data and future plans (Phase 3 initiation), it fits best as a general regulatory announcement or a specific type of investor communication. Given the options, it is a press release announcing clinical progress, which often falls under general Regulatory Filings (RNS) if no other specific category applies. However, because it is a detailed report on clinical trial results and future development plans, it is often categorized as an Investor Presentation (IP) or a general Regulatory Filing (RNS). Since it is a press release format announcing results and future steps, and not a formal presentation deck, RNS is the most appropriate fallback for a non-standard, material announcement. It is not short enough to be a simple RPA.
2016-04-22 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. It references a press release dated April 21, 2016, attached as Exhibit 99.1. The document length is only 1490 characters, which is quite short and primarily serves as a cover report to submit the press release. There is no substantive financial data or detailed report content within this document itself. According to the 'Menu vs Meal' rule, such short filings that announce or attach other reports or press releases should be classified as Regulatory Filings (RNS). Therefore, this document is best classified as a Regulatory Filing (RNS).
2016-04-22 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.